BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260717
DTSTAMP:20260514T232712
CREATED:20260318T153844Z
LAST-MODIFIED:20260318T153844Z
UID:43179-1783987200-1784246399@www.pharmajournalist.com
SUMMARY:4th Obesity & Weight Loss Drug Development Summit
DESCRIPTION:Welcome to the 4th Obesity & Weight Loss Drug Development Summit – the definitive industry-forum dedicated to redefining the standards of metabolic medicine by mastering precision treatment\, preserving functional health\, and navigating the high-stakes transition to next-generation oral and multi-agonist therapies. \nThe obesity therapeutics market has entered a radical transformation. Driven by the unprecedented success of first-generation incretins\, the landscape has reached a critical juncture where “simple weight loss” is no longer enough to win. As we move through 2026\, the industry is under intense pressure to move beyond BMI-centric endpoints and unlock new levels of quality\, targeting the 40% of adults globally who require more than a one-size-fits-all approach. The race is now on to decouple adipose reduction from skeletal muscle atrophy and secure long-term adherence through needle-free\, scalable solutions that promise to transform chronic disease management forever. \nThe 4th Obesity & Weight Loss Drug Development Summit stands as the essential global forum for experts dedicated to accelerating this vital progress. This year\, we are diving deep into the game-changing potential of multi-targeted portfolios\, novel biological pathways and new modalities for a precision medicine approach\, alongside the “Oral-First” revolution. \nHear from the titans of the pharmaceutical industry\, including Novo Nordisk\, Eli Lilly\, and Merck & Co.\, as well as innovative biotechs such as Veru Inc.\, Canary Cure\, and Metsera\, who will share their ground-breaking research on preserving lean mass and preventing post-treatment weight regain. \nDon’t miss this pivotal opportunity to network with 120+ leading experts in the field of advanced obesity therapeutics. Forge crucial collaborations and be part of the solution that will define the 2026 pipeline. \nView the full event guide: https://ter.li/p453jn
URL:https://www.pharmajournalist.com/event/4th-obesity-weight-loss-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260717
DTSTAMP:20260514T232712
CREATED:20260506T130245Z
LAST-MODIFIED:20260506T130245Z
UID:43444-1783987200-1784246399@www.pharmajournalist.com
SUMMARY:2nd Operationalize: Expanded Access Programs Summit West
DESCRIPTION:Across the West Coast\, Expanded Access Programs are entering a new phase. More companies are launching EAPs earlier in development\, supporting patients for longer durations\, and extending access beyond the U.S. into increasingly complex global markets. What was once a reactive\, exception-based activity is now a visible\, repeatable function – bringing heightened expectations around governance\, post-trial access\, sustainability\, and real-world insight generation\, all while ensuring patients are not delayed or disadvantaged. \nThe 2nd Operationalize: Expanded Access Programs Summit West arrives at a critical moment. Purpose-built for West Coast biotech and pharma teams\, this summit brings together senior leaders across Access\, Medical Affairs\, Clinical Operations\, Regulatory\, and Clinical Supply to share how EAPs are being designed\, governed\, and scaled in today’s environment. \nOver three focused days\, the summit tackles the most pressing questions facing EAP teams in 2026 – from navigating evolving U.S. and global regulatory expectations\, to enabling providers and patient advocates\, designing post-trial access strategies\, managing long-duration and rare disease programs\, and applying real-world insights without slowing access. \nThis is not a theoretical discussion. It is a peer-led\, non-competitive forum for teams responsible for delivering access at scale – and for those shaping what Expanded Access must become next. \nTo know more visit: https://ter.li/gk0u1gt1
URL:https://www.pharmajournalist.com/event/2nd-operationalize-expanded-access-programs-summit-west/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point Street\, San Francsico\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260720
DTEND;VALUE=DATE:20260723
DTSTAMP:20260514T232712
CREATED:20260312T132559Z
LAST-MODIFIED:20260312T132559Z
UID:43120-1784505600-1784764799@www.pharmajournalist.com
SUMMARY:6th mRNA-Based Therapeutics Summit
DESCRIPTION:The 6th mRNA‑Based Therapeutics Summit: Accelerating the Next Era of mRNA Medicines \nThe global mRNA landscape is advancing at unprecedented speed\, propelled by scientific breakthroughs and high‑impact biopharma investment. Recent acquisitions – including Eli Lilly and Orna\, BMS and Orbital\, AbbVie and Capstan\, and BioNTech and CureVac – underscore the momentum behind emerging modalities such as in vivo CAR‑T\, gene editing\, and cancer immunotherapies as they move closer to clinical validation and commercial potential. \nAmid this rapid evolution\, the 6th mRNA‑Based Therapeutics Summit returns to Boston this summer as the world’s most influential meeting dedicated to mRNA science and drug development. Bringing together 350+ global leaders from established pharma innovators to trailblazing start‑ups – including Moderna\, Pfizer\, AstraZeneca\, Sanofi\, ParcelBio\, CaVos Therapeutics and Kernal Biologics – as well as regulators from the US FDA\, MHRA and EMA\, the summit serves as the central forum shaping the future of mRNA technology. \nThis year’s revitalized agenda spans three core tracks – Discovery\, Pre‑Clinical & Clinical Development\, and Manufacturing & CMC – while introducing two brand‑new focus days on AI‑Driven mRNA Design and Next‑Generation Delivery Technologies. Across scientific sessions\, case studies\, and collaborative discussions\, attendees will gain exclusive access to emerging data\, regulatory expectations\, and the partnerships driving mRNA toward its next frontier. \nWith 1\,988 mRNA assets currently moving through global pipelines\, the field is scaling faster than ever. The 2026 summit is strategically timed to spotlight major advancements across linear\, circular\, and self‑amplifying RNA platforms; next‑generation vaccine innovation and expanding clinical progress in oncology\, rare diseases\, autoimmune conditions\, and beyond. \nAs the flagship global gathering for mRNA innovators\, this summit remains the definitive place to connect with key decision makers\, forge new strategic partnerships\, and refine development and delivery strategies. From protein replacement to cell and gene therapeutics and transformative delivery technologies\, the 6th mRNA‑Based Therapeutics Summit equips teams with the insights\, networks\, and momentum needed to accelerate candidates to clinical and commercial success and ultimately deliver life‑changing medicines to patients worldwide. \nTo know more visit: https://ter.li/axdw1v
URL:https://www.pharmajournalist.com/event/6th-mrna-based-therapeutics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260720
DTEND;VALUE=DATE:20260723
DTSTAMP:20260514T232712
CREATED:20260320T111737Z
LAST-MODIFIED:20260320T111820Z
UID:43198-1784505600-1784764799@www.pharmajournalist.com
SUMMARY:5th Liquid Biopsy for Precision Oncology Summit East Coast
DESCRIPTION:The 5th Liquid Biopsy for Precision Oncology Summit East Coast returns as your laser-focused forum dedicated to the acceleration\, progression and real-world adoption of liquid biopsies. Expect to unite with 100+ biopharma professionals from Pfizer\, AbbVie\, Takeda\, AstraZeneca\, GSK and more to redefine your clinical trial strategies and advance oncology drug development forward. \nBoasting a speaker faculty consisting of over 70% large pharma\, alongside leading biotech and consortia\, this year’s meeting will not just be a forum to listen. It will be where the practical conversations shaping future decisions on patient stratification\, MRD implementation and dose optimization happen in real time. \nTake a sneak peek at what lies ahead this year: \n\nIdentify why pharma must be the ones to lead early detection in a session led by the Global Senior Director\, Early Detection at AstraZeneca\nUtilize ctDNA dynamics as an early measure of treatment effect to go beyond RECIST in a presentation hosted by the Chief Executive Officer at Marengo Therapeutics\nHear how senior pharma leaders at AbbVie\, Takeda\, AstraZeneca and GSK are rewriting drug development decisions with novel liquid biopsies\nDiscover how you can accelerate clinical development with ctDNA clearance and multi-omic profiling in an exclusive discussion moderated by the Director\, Next-Generation Diagnostics at Novartis\n\nWhether you’re evaluating the right liquid biopsy platform for your specific trial\, looking to gain peer-insight into ctDNA and multi-omic profiling\, or aligning internal strategies with evolving regulatory expectations\, this meeting will provide you with the clarity\, and confidence to take that next step. \nTogether let’s harness the power of liquid biopsies to drive smarter\, better and more precise clinical decisions for patients in need. \nTo learn more and register\, please click here.
URL:https://www.pharmajournalist.com/event/5th-liquid-biopsy-for-precision-oncology-summit-east-coast/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260721
DTEND;VALUE=DATE:20260724
DTSTAMP:20260514T232712
CREATED:20260326T113151Z
LAST-MODIFIED:20260326T113151Z
UID:43220-1784592000-1784851199@www.pharmajournalist.com
SUMMARY:6th Medical Device Software Development Summit
DESCRIPTION:The 6th Medical Device Software Development Summit returns this July in Boston and brings together the specialists who are defining how AI-driven and software-based medical devices are built\, validated\, and submitted in an increasingly complex regulatory environment. \nAI is accelerating innovation faster than traditional compliance models can keep up. FDA expectations for AI-enabled devices continue to evolve\, cybersecurity scrutiny is intensifying\, and global regulations such as the EU AI Act are adding new layers of complexity. The summit provides the clarity needed to navigate this shift by focusing on the real-world application of AI\, automation\, model development\, and lifecycle management in regulated device environments. \nAcross three days of technical sessions and workshops\, you will learn how leading teams are integrating AI responsibly\, reducing regulatory risk\, and strengthening product development pipelines. Speakers will break down practical frameworks for safe and compliant AI integration\, including model validation\, data quality\, transparency expectations\, documentation strategies\, and global submission planning. Sessions also explore how continuous deployment and code generation tools can be aligned with compliance requirements. \nYou will: \n\nGain clear insight into evolving FDA expectations for AI-enabled and learning devices\nLearn best practices for AI model development\, validation\, and deployment across the product lifecycle\nExplore cybersecurity architectures that protect AI-driven systems from emerging risks\nUnderstand how companies are modernizing development workflows through automation and AI-assisted engineering while maintaining compliance\nBenchmark with software\, regulatory\, quality\, cybersecurity\, and product leaders who openly share real-world implementations and lessons\n\nWith a focused senior-level audience\, discussions are practical\, detailed\, and grounded in real use cases instead of high-level theory. If your team is building or validating AI-enabled medical device software in 2026\, this summit is the most concentrated source of guidance on how to innovate safely\, accelerate approvals\, and future-proof your roadmap in a rapidly shifting landscape. \nJoin the community leading the next generation of AI-driven medical device software and gain the insight and tools needed to advance your program with confidence. \nTo learn more and register online\, please click here.
URL:https://www.pharmajournalist.com/event/6th-medical-device-software-development-summit/
LOCATION:Hotel AKA Back Bay\, 154 Berkeley St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260721
DTEND;VALUE=DATE:20260724
DTSTAMP:20260514T232712
CREATED:20260430T111342Z
LAST-MODIFIED:20260430T111342Z
UID:43429-1784592000-1784851199@www.pharmajournalist.com
SUMMARY:9th International Neoantigen Summit
DESCRIPTION:As the only conference focused on neoantigens\, the 9th International Neoantigen Summit returns to Amsterdam as the most timely and essential gathering for the field. As your only chance this year to learn about the latest clinical data in the field and address the full translational journey – from antigen identification and validation through to biomarker strategy\, clinical trial readouts and therapeutic efficacy – it’s not one to miss. \nWith a sharp focus on optimising translational testing\, strengthening neoantigen validation and advancing novel personalised and off‑the‑shelf approaches\, the conference is designed to help the industry streamline clinical trials and develop durable therapies with high immune response. \nOver 3 immersive days\, the summit will unite 70+ C‑level executives\, directors\, heads and senior scientists from leading biopharma organisations across Europe and the US. Attendees span: \n\nCancer immunotherapy\nAntigen discovery\nBioinformatics\nAI‑driven validation\nPreclinical and clinical development\nRegulatory strategy\n\nAll brought together by a shared mission to unlock the full potential of neoantigen‑targeted therapies. \nWith 6 new speaking companies\, including Black Canyon Bio\, CellVax Therapeutics\, Echo Immune\, Epitopea\, Khosen Bio and Treos Bio\, the summit convenes industry pioneers including Nykode Therapeutics\, Evaxion\, Geneos\, and other leading innovators shaping the next generation of immunotherapies. Every session is curated for relevance\, and every interaction is designed to foster meaningful collaboration. \nParticipants can expect critical clinical data updates\, practical insights into bioinformatics and AI applications\, strategies for clinical trial design and execution\, and guidance on translating preclinical findings into successful clinical outcomes. More than a conference\, this is the only annual checkpoint for the neoantigen community – a one‑stop platform to benchmark progress\, uncover breakthroughs and build the partnerships that will drive the next wave of neoantigen‑targeted therapies forward.
URL:https://www.pharmajournalist.com/event/9th-international-neoantigen-summit/
LOCATION:Park Plaza Amsterdam Victoria\, Damrak 1-5\, 1012 LG\, Amsterdam\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260728
DTEND;VALUE=DATE:20260731
DTSTAMP:20260514T232712
CREATED:20260312T131240Z
LAST-MODIFIED:20260312T131240Z
UID:43114-1785196800-1785455999@www.pharmajournalist.com
SUMMARY:4th ADC Linker & Conjugation Summit
DESCRIPTION:4th ADC Linker & Conjugation Summit\nLinking Chemistry to Clinical Success Through Better ADC Design \n\nWhen? July 28-30\, 2026\nWhere? Boston\, MA\n\nADC development is evolving fast\, with developers pushing beyond traditional cytotoxins into dual‑payload constructs\, high‑DAR species\, degrader–antibody conjugates\, and next‑generation modalities. This surge in innovation is placing new pressure on linker architecture and conjugation chemistry to improve stability\, reduce off‑target toxicity\, and maintain manufacturability at scale. \nThe 4th ADC Linker & Conjugation Summit returns this July as the only meeting dedicated exclusively to overcoming these chemistry‑centric challenges. Built specifically for ADC chemists\, protein engineers\, and bioconjugation specialists\, the summit offers a highly curated setting where every session speaks directly to the scientific bottlenecks shaping next‑generation ADC performance. Attendees join peers with the same technical focus\, ensuring every conversation is relevant and grounded in real‑world ADC development needs.Across three focused days\, more than 80 scientific experts will dissect the mechanisms driving linker stability\, conjugation precision\, and payload behavior. The program features 20+ industry‑led case studies covering homogeneous ADC design\, controlling premature payload release\, dual‑payload engineering\, hydrophobicity‑driven aggregation\, and the integration of predictive modeling into conjugation strategies. These sessions reflect broader industry priorities\, where site‑specific conjugation\, next‑generation linkers\, and stability optimization remain top areas of innovation. \nThis year introduces expanded workshops and interactive debates\, including new sessions examining how to more effectively connect linker chemistry to translational outcomes and how to redesign payloads using emerging linker technologies. The 2026 meeting also welcomes 17 new speakers from 13 new companies\, offering fresh insight into the rapidly diversifying toolkit available for ADC design. \nFor scientists working at the core of ADC chemistry\, this summit provides a rare opportunity to benchmark strategies\, challenge assumptions\, and contribute to the next decade of linker and conjugation innovation. \nView the full program and explore the 2026 agenda \nDownload the event guide here: https://ter.li/7pj7r6
URL:https://www.pharmajournalist.com/event/4th-adc-linker-conjugation-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260728
DTEND;VALUE=DATE:20260731
DTSTAMP:20260514T232712
CREATED:20260326T114512Z
LAST-MODIFIED:20260326T114512Z
UID:43226-1785196800-1785455999@www.pharmajournalist.com
SUMMARY:5th In Vivo Cell Engineering & Gene Editing Summit
DESCRIPTION:The 5th In Vivo Cell Engineering & Gene Editing Summit returns as the leading industry meeting dedicated to advancing the next generation of in vivo delivery platforms\, gene editing tools\, and translational strategies that support safe\, precise\, and scalable genetic medicines. Designed for scientists\, technical leaders\, and strategic decision-makers across biopharma\, this summit provides a focused forum to exchange practical insights that directly influence scientific and clinical progress. \nThis year’s faculty brings together experts from cutting-edge biotechnology companies and global pharmaceutical organizations\, including leaders from AstraZeneca\, Pfizer\, Eli Lilly\, Ensoma\, Capstan Therapeutics\, Verve Therapeutics\, nChrioma Bio\, and more. Their collective experience spans delivery system innovation\, payload engineering\, translational development\, and early clinical execution\, giving delegates a clear view of what is required to successfully advance in vivo platforms. \nOver three days of data-driven discussion\, attendees will explore the latest advancements in lipid nanoparticle engineering\, viral and nonviral vector optimization\, capsid evolution\, and emerging delivery technologies for targeted\, efficient editing. Sessions will detail how teams are engineering payloads to enhance potency\, durability\, safety\, and manufacturability. Speakers will also share frameworks for designing rigorous preclinical packages that address biodistribution\, immunogenicity\, and off-target risk early in development. \nThe summit places a strong focus on translational and early clinical learnings\, with case studies that reveal how organizations are approaching dose selection\, biomarker development\, patient monitoring\, and regulatory positioning. These insights provide an unfiltered look at what has worked in real programs and how teams are adjusting strategies to improve clinical readiness. \nDelegates will benefit from a mix of scientific depth and strategic clarity. Whether you are building new delivery platforms\, advancing editing tools\, refining analytical approaches\, or preparing a therapy for first-in-human studies\, this meeting helps you benchmark your progress and sharpen decision-making. \nJoin peers who are driving the future of in vivo gene editing and cell engineering. This summit delivers the connections\, evidence-based insights\, and collaborative environment needed to progress transformative genetic medicines. \nTo learn more and register online\, please click here.
URL:https://www.pharmajournalist.com/event/5th-in-vivo-cell-engineering-gene-editing-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR